Study Explores How Coffee May Protect the Liver

The signal is broad, but still observational

Cedars-Sinai investigators analyzed data from 354,957 UK Biobank participants who did not have cirrhosis or liver cancer at the start of the study. Over a median follow-up of 13 years, they tracked new diagnoses of cirrhosis, liver cancer, and liver-related death through linked health records.

Compared with people who did not drink coffee, those drinking five or more cups per day had:

• 32% lower risk of cirrhosis;
• 47% lower risk of liver cancer;
• 42% lower risk of liver-related death.

Those figures are clinically interesting because the endpoints are not soft wellness markers. Cirrhosis, liver cancer, and liver-related mortality are hard outcomes. However, the study design remains observational. It can identify association; it cannot prove that coffee itself prevents liver disease.

That distinction is not academic pedantry. Coffee drinkers may differ from non-drinkers in other ways that affect hepatic risk. The investigators therefore appropriately stop short of recommending that people start drinking coffee solely for liver protection.

Mechanistic clues: MRI and blood proteins

The more useful part of the report is the biological triangulation. According to Cedars-Sinai, participants who drank more coffee also had lower levels of liver fat, liver iron, fibrosis, and liver inflammation on MRI scans. Blood tests showed higher levels of proteins tied to healthy liver function and lower levels of proteins linked to scarring and inflammation.

This matters because many nutrition headlines lean on outcome associations alone. Here, the signal is supported by intermediate biological markers that plausibly sit along the pathway from metabolic stress to liver injury. In biochemical terms, the study does not prove causality, but it reduces the likelihood that the finding is merely a statistical curiosity.

The caffeine question is also constrained by the data. Similar protective associations were observed for caffeinated and decaffeinated coffee. That suggests caffeine is unlikely to be the sole active component. Other naturally occurring compounds in coffee may be contributing, although the report does not establish which compounds, in what dose, or with what pharmacokinetic profile.

Practical interpretation: moderate use, not escalation

Cedars-Sinai reports that risk decreased as coffee consumption increased, with benefits seen even at one to two cups per day and appearing strongest around three to four cups per day. The highest intake group, five or more cups daily, showed benefit, but the researchers explicitly did not recommend increasing consumption to that level specifically.

The practical reading is narrow:

• People who already drink coffee and tolerate it well have some observational reassurance that moderate intake is compatible with favorable liver-health markers.
• Decaffeinated coffee cannot be dismissed, given the similar association reported for caffeinated and decaffeinated forms.
• Coffee should not displace established liver-risk reduction strategies.

The senior study author, Ju Dong Yang, MD, emphasized that prevention should still focus on maintaining a healthy weight, limiting alcohol, exercising regularly, and managing blood sugar, blood pressure, and cholesterol.

Verdict: statistically and biologically interesting, but not prescriptive. The data support moderate coffee consumption as a reasonable dietary pattern for people who already use it comfortably. They do not justify treating coffee as liver prophylaxis, nor do they justify pushing intake toward five cups per day in pursuit of a biochemical advantage that remains associative rather than proven.